Dar Al Dawa Development and Investment (DADI) Stock Overview
Dar Al Dawa Development and Investment Co. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
DADI Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Dar Al Dawa Development and Investment Co. Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | د.أ1.17 |
| 52 Week High | د.أ1.36 |
| 52 Week Low | د.أ1.12 |
| Beta | 0.24 |
| 1 Month Change | 0.86% |
| 3 Month Change | -7.14% |
| 1 Year Change | -10.00% |
| 3 Year Change | 15.84% |
| 5 Year Change | 15.84% |
| Change since IPO | -71.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| DADI | JO Pharmaceuticals | JO Market | |
|---|---|---|---|
| 7D | 0.9% | 4.1% | 0.8% |
| 1Y | -10.0% | 13.8% | 19.6% |
Return vs Industry: DADI underperformed the JO Pharmaceuticals industry which returned 13.8% over the past year.
Return vs Market: DADI underperformed the JO Market which returned 19.6% over the past year.
Price Volatility
| DADI volatility | |
|---|---|
| DADI Average Weekly Movement | 2.7% |
| Pharmaceuticals Industry Average Movement | 6.2% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in JO Market | 6.1% |
| 10% least volatile stocks in JO Market | 2.8% |
Stable Share Price: DADI has not had significant price volatility in the past 3 months compared to the JO market.
Volatility Over Time: DADI's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1975 | 1,111 | Khaled Abedalhameed Harb | www.dadgroup.com |
Dar Al Dawa Development and Investment Co. Ltd., an integrated pharmaceutical company, develops, manufactures, markets, and distributes pharmaceutical and consumer healthcare products in Levant, Gulf and Yemen, the Middle East, Africa, Europe, and Asia. It operates through Medicine; and Infants’ Cereals and Milk Formula segments. The company offers products in the therapeutic areas of anti-infective, cardiovascular and diabetes, urology, respiratory, gastrointestinal, analgesic and musculoskeletal, central nervous system, gynecology, dermatology, ophthalmology, and oncology; and cereal and milk formula products for infants.
Dar Al Dawa Development and Investment Co. Ltd. Fundamentals Summary
| DADI fundamental statistics | |
|---|---|
| Market cap | د.أ40.95m |
| Earnings (TTM) | د.أ3.68m |
| Revenue (TTM) | د.أ82.88m |
Is DADI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DADI income statement (TTM) | |
|---|---|
| Revenue | د.أ82.88m |
| Cost of Revenue | د.أ49.83m |
| Gross Profit | د.أ33.05m |
| Other Expenses | د.أ29.37m |
| Earnings | د.أ3.68m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.11 |
| Gross Margin | 39.88% |
| Net Profit Margin | 4.45% |
| Debt/Equity Ratio | 101.5% |
How did DADI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/13 19:44 |
| End of Day Share Price | 2025/06/12 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Dar Al Dawa Development and Investment Co. Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kais Kriaa | AlphaMena |